[Bone-seeking radiopharmaceuticals in evaluating the treatment of skeletal metastases of malignant tumors].
Data on 97 patients were analysed. Of these, 42 received combined therapy, 30 radiotherapy and 25 chemotherapy. The utmost therapeutic effect (by the selected criteria) was obtained with combined treatment (88.1%). Radionuclide signs of the efficacy of radiotherapy were noted in 70% of the patients, whereas 23.3% did not respond. The least effect was obtained with chemotherapy: the absence of improvement or deterioration were noted in 48% of the patients. The correlation of the data obtained with the clinical ones (the painful syndrome) was observed. A high sensitivity of the method does not only help reveal pathological skeletal changes but also plan adequate therapy.
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D003131:Combined Modality Therapy; D011756:Diphosphates; D004164:Diphosphonates; D005260:Female; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000628:therapy*; D011877:Radionuclide Imaging; D013667:Technetium; D017556:Technetium Compounds; D016698:Technetium Tc 99m Pyrophosphate
D011756:Diphosphates; D004164:Diphosphonates; D017556:Technetium Compounds; D016698:Technetium Tc 99m Pyrophosphate; D013667:Technetium; C029045:technetium Tc 99m diphosphonate
Osteotropnye RFP v otsenke lecheniia metastazov zlokachestvennykh opukholeĭ v skelet.